Acute Dyspnea From Treatment of AL Amyloidisis With Bortezomib

Abstract

Bortezomib with or without dexamethasone has been reported to be very effective and well tolerated in the treatment of AL amyloidosis. Commonly reported adverse effects are fatigue, nausea, vomiting, diarrhea, constipation, postural hypotension from autonomic neuropathy, peripheral neuropathy, thrombocytopenia and anemia. Dyspnea has been rarely reported as an adverse effect of bortezomib therapy in AL amyloidosis. We are reporting three case reports of patients suffering from AL amyloidodis, who had new onset acute dyspnea secondary to bortezomib treatment that required drug discontinuation. There might be some correlation between the AL amyloidosis disease and bortezomib associated dyspnea, but the pathophysiology is poorly understood.

A Case of Multiple Myeloma with Metachronous Chronic Myeloid Leukemia Treated Successfully with Bortezomib, Dexamethasone, and Dasatinib

“…Pulmonary arterial hypertension is a known complication of dasatinib and is commonly seen after 8 to 48 months of treatment [ 21 – 24 ]. Although less common, pulmonary arterial hypertension has been reported with bortezomib as well [ 25 , 26 ]. It was unclear if dasatinib was the only culprit in our patient's pulmonary hypertension as he also sustained a cardiac event and he later admitted to taking an unknown “diet pill” which might have all contributed to developing pulmonary hypertension.…”

Bortezomib Dendrimer Prodrug‐Based Nanoparticle System

“…Clinical studies have indicated that patients suffer from cardiomyocytes necrosis along with liver and kidney damage after three months of treatment with BTZ . Patients also suffer from other side effects, such as nausea, vomiting, diarrhea, and even shock . As a commercial drug comprising a chelate of BTZ and mannitol, Velcade could not be transported to tumor tissues effectively.…”